secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001628280-25-004514
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M
--------------------------------------------------------------------------------

- Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).
- Jakafi net revs Q4 $773M (+11% YoY), FY $2.79B (+8%); Opzelura Q4 $162M (+48%), FY $508M (+50%).
- FY2025 guidance: Jakafi $2,925-2,975M; Opzelura $630-670M; other oncology $415-455M.
- Pipeline catalysts: Niktimvo launched; ruxolitinib XR bioequivalence met, submission by year-end 2025; four pivotal readouts in 2025.
- Cash and securities $2.2B at Dec 31, 2024, down from $3.7B due to $2B share repurchase and $783M Escient acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/0001628280-25-004514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-20250210.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-004514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer